Home >
Scientific Programmes: Biotechnology Programme >
Transgenic Mice Core Unit
Scientific Programmes
Biotechnology Programme
Transgenic Mice Core Unit
Head of Unit:
Sagrario Ortega
Publications in the last five years
Pages 1 - 2
- Li H, Collado M, Villasante A, Strati K, Ortega S, Cañamero M, Blasco MA, Serrano M (2009). The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 460, 1136-1139.
- Marión RM, Strati K, Li H, Murga M, Blanco R, Ortega S, Fernandez-Capetillo O, Serrano M, Blasco MA (2009). A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 460, 1149-1153.
- Marion RM, Strati K, Li H, Tejera A, Schoeftner S, Ortega S, Serrano M, Blasco MA (2009). Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells. Cell Stem Cell 4, 141-154.
- Parra D, Manils J, Castellana B, Viña-Vilaseca A, Morán-Salvador E, Vázquez-Villoldo N, Tarancón G, Borràs M, Sancho S, Benito C, Ortega S, Soler C (2009). Increased susceptibility to skin carcinogenesis in TREX2 knockout mice. Cancer Res 69, 6676-6684.
- Viera A, Rufas JS, Martínez I, Barbero JL, Ortega S, Suja JA (2009). CDK2 is required for proper homologous pairing, recombination and sex-body formation during male mouse meiosis. J Cell Sci 122, 2149-2159.
- Marzo N, Ortega S, Stratmann T, García A, Ríos M, Giménez A, Gomis R, Mora C (2008). Cyclin-dependent kinase 4 hyperactivity promotes autoreactivity in the immune system but protects pancreatic Beta cell mass from autoimmune destruction in the nonobese diabetic mouse model. J Immunol 180, 1189-1198.
- Gómez C, Domínguez V, Martín J, Riffo M, Muñoz J, Ortega S (2008). ES cell culture and derivation. Transgenic Res 17, 997-997.
- Barriere C, Santamaría D, Cerqueira A, Galán J, Martín A, Ortega S, Malumbres M, Dubus P, Barbacid M (2007). Mice thrive without Cdk4 and Cdk2. Mol Oncol 1, 72-83.
- Santamaria D, Ortega S (2006). Cyclins and CDKS in development and cancer: lessons from genetically modified mice. Front Biosci 11, 1164-1188.
- Martín A, Odajima J, Hunt SL, Dubus P, Ortega S, Malumbres M, Barbacid M (2005). Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1). Cancer Cell 7, 591-598.
Pages 1 - 2
